Business Wire

 Knopp Biosciences to Present Data Characterizing Its Kv7 Technology Platform’s Potential for Delivering Precision Medicines to Treat Diverse Neurological and Smooth Muscle Diseases

Share

Knopp Biosciences LLC today reports data demonstrating that compound subgroups from its proprietary library of potassium-channel modulators selectively target Kv7 channel subtypes associated with a wide range of neurological and smooth muscle diseases. The data is being presented at the International Kv7 Channels Symposium 2019 in Naples, Italy.

Presentation Title: The Re-emergence of Kv7 Drug Discovery
Presenter: Michael Bozik, M.D., CEO, Knopp Biosciences
Date & Time: September 13, 4:35 pm CEST

Michael Bozik, M.D., Chief Executive Officer of Knopp, will present the data derived from the Company’s proprietary library of more than 3,000 novel compounds directed to modulating the Kv7 channel, which regulates the flow of potassium ions across cell membranes. The data demonstrate that specific subgroups of Kv7 compounds selectively modulate different Kv7 channel subtypes across ranges of channel activation and inhibition, enabling selection of compounds capable of targeting neurological disorders associated principally with Kv7.2/7.3 channels and others associated principally with Kv7.4 channels.

“By characterizing a custom library of Kv7 modulators for activity and specificity, we have shown evidence of the potential to develop targeted treatments for diverse diseases of the central nervous system and smooth muscle,” said Dr. Bozik. “Accordingly, we believe our Kv7 library represents a precision tool-set for investigating Kv7 pharmacology across a wide range of therapeutic areas with high unmet need.”

Engineered cell lines expressing the channel subtypes Kv7.2/7.3, Kv7.4, Kv7.3/7.5, and Kv7.1/KCNE1 were used in a screening format to characterize compound activity. A thallium flux assay was the primary screen to determine effective concentration values (EC50) for Kv7.2/7.3 activity and to rank-order compounds. Active compounds were then counter-screened against other Kv7 cell lines. The QPatch HTx automated patch-clamp system provided a confirmatory functional assay to further characterize the electrophysiology properties of these novel compounds.

Knopp’s lead Kv7 modulator, KB-3061, is in preclinical development for KCNQ2 epileptic encephalopathy, a rare neonatal disease characterized by seizures beginning in the first days of life and by significant developmental delay.

ABOUT KNOPP BIOSCIENCES LLC

Knopp Biosciences is a privately held drug discovery and development company focused on delivering breakthrough treatments for neurological and immunological diseases of high unmet need. In addition to developing oral dexpramipexole for eosinophil-associated diseases, Knopp’s preclinical Kv7 platform is directed to small molecule treatments for KCNQ2 epileptic encephalopathy and other CNS hyperexcitability disorders. Please visit www.knoppbio.com.

This press release contains "forward-looking statements," including statements relating to planned regulatory filings and clinical development programs. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including the uncertainties inherent in clinical trials and product development programs, the availability of funding to support continued research and studies, the availability or potential availability of alternative therapies or treatments, the availability of patent protection for the discoveries and strategic alliances, as well as additional factors that may cause Knopp's actual results to differ from our expectations. There can be no assurance that any investigational drug product will be successfully developed or manufactured or that final results of clinical studies will be supportive of regulatory approvals required to market a product. Knopp undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Knopp's pipeline consists of investigational drug products that have not been approved by the U.S. Food and Drug Administration. These investigational drug products are still undergoing clinical study to verify their safety and effectiveness.

Contact information

Media inquiries:
James Heins
james.heins@icrinc.com
203-682-8251

Surabhi Verma
surabhi.verma@icrinc.com
646-677-1825

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Alpega TMS Shows Impressive Triple-digit Growth in Expanding SME Segment17.2.2020 18:00:00 EETPress release

Alpega Group, the leading provider of cloud-based, end-to-end transportation and logistics management software in Europe, today announced that new business from its TMS software grew by 100% in the SME segment in 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200217005017/en/ Todd DeLaughter, Alpega Group CEO (Photo: Business Wire) Speaking on the results, Todd DeLaughter, Group CEO for Alpega said: “While the TMS market as a whole is growing in the high teens, we saw particular acceleration in the SME segment as more and more mid-size companies embrace technology to enable business efficiency and reduce cost while lowering carbon emissions. In 2019, we added 83 new clients for our TMS business.” “A big part of this success is down to the flexibility we offer our users. By bringing together the expertise of inet, Transwide and TenderEasy, Alpega TMS is able to cater to businesses dealing with all levels of logistics co

GSMA Board Statement on MWC Barcelona 202017.2.2020 18:00:00 EETPress release

The GSMA Board would like to express its sadness at the unavoidable cancellation of MWC Barcelona 2020. This decision is painful, but we believe the correct one. Health and safety are the priorities of all of the GSMA Board and Mobile Network Operators. Our sincere thoughts are with those affected in China and around the world in these trying times. Our vision at the GSMA is to unlock the power of connectivity so that people, industry and society thrive. MWC is crucial to convene and advance the industry and mobile ecosystem. The mobile industry is committed to harnessing the power of mobile technology and connectivity to transform the lives of billions of people around the world, and we are committed to a great MWC Barcelona 2021. The Board thanks GSMA management and the Host City Parties for their hard work throughout this challenging and unprecedented situation. We look forward to working together again for an even better MWC Barcelona 2021. The GSMA Board is comprised of 25 of the

Mary Kay Inc. Announces Actress, Philanthropist Monique Coleman as First-Ever Pink Changing Lives Honoree17.2.2020 17:00:00 EETPress release

Mary Kay Inc., a long-time leader in global female empowerment, is proud to announce Monique Coleman has been named the brand’s first-ever Pink Changing Lives Honoree. Pink Changing Lives—Mary Kay’s global commitment to celebrate the individuals and organizations that improve women’s and girls’ lives around the world—has supported more than three million women and their families by partnering with over 2,000 organizations and donating over $15 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200217005216/en/ Monique Coleman has been named Mary Kay Inc. first-ever Pink Changing Lives Honoree. (Photo: Mary Kay Inc.) Mary Kay’s Pink Changing Lives cause empowerment program donates funds to organizations focused on supporting cancer research, helping end hunger, protecting survivors from domestic abuse, beautifying communities, and many other programs empowering women and girls. In 2020, Mary Kay created the Pink Changing

ABS, the Royal Canadian Navy, and Defence Research & Development Canada Launch Digital Asset Framework Pilot17.2.2020 16:00:00 EETPress release

ABS today announced it is engaged in a pilot program with the Royal Canadian Navy (RCN) and Defence Research and Development Canada (DRDC) to deliver the ABS Digital Asset Framework for the RCN’s Maritime Coastal Defence Vessels. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200217005014/en/ The HCMS Saskatoon (Photo: Business Wire) The ABS Digital Asset Framework forms the foundation of a broader Conditioned-Based Class program that transforms ship classification from a calendar-based schedule to a condition-based model. The project, which will start with HMCS Saskatoon, will support the RCN’s larger Digital Navy Initiative. “ABS is a leader in delivering condition-based maintenance data services in maritime and offshore applications, and we are proud that the RCN have chosen to work with us on this landmark project,” said Christopher J. Wiernicki, ABS Chairman, President and CEO. “Through our digital programs for commerci

Oasis Is Proud to Announce the Availability of HELIOS 5G, its Latest Release of Secure UICC Operating System17.2.2020 14:15:00 EETPress release

HELIOS 5G proposes enhanced security capabilities to secure critical communication services and respond actively to the greater range of possible threats associated with the wider variety of actors and devices types expected on the fifth generation of mobile network. Among many improvements implemented by Oasis R&D team, HELIOS 5G introduces new features to enable a device to authenticate to the 5G network with increased security and privacy of communications. The network authentication offered by Helios 5G is significantly stronger, due to longer crypto keys and an advanced algorithm. Additionally, the HELIOS OS benefits from a powerful onboard encryption including a SUCI calculator. It anonymizes the subscriber identity, thereby guaranteeing full subscriber privacy. Patrick Cao, Chief Operating Officer, said: “HELIOS 5G is an important milestone in the development history of our Helios SIM and eSIM Operating System. It demonstrates the expertise of our R&D team and confirms our posit

1.86 Customer Minutes Lost (CML) of Electricity per Year in Dubai17.2.2020 13:08:00 EETPress release

Dubai Electricity and Water Authority (DEWA) has achieved a new world record in electricity Customer Minutes Lost (CML) per year. DEWA recorded 1.86 minutes, in Dubai, compared to around 15 minutes recorded by leading electricity companies in the European Union. This is a new addition to DEWA’s record of international achievements in electricity and water services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200217005093/en/ Dubai Electricity and Water Authority (DEWA) achieves a new world record in electricity Customer Minutes Lost (CML) per year and enhances Dubai’s prosperity. (Photo : AETOSWire). “At DEWA, we work according to the vision and directives of our leadership to provide a robust infrastructure according to the highest international standards. We continuously work to enhance the capacity and efficiency of transmission and distribution networks to provide electricity and water services according to the highes

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom